GlassScriptPhysician profile
Elizabeth Ilog
NPI 1861079121
$3,974.75
in general payments reported to CMS, 2019-2025
21 companies · $821 in 2025
The $821 reported for 2025 was more than what 77% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $984 · 2022: $271 · 2023: $810 · 2024: $1,090 · 2025: $821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,720.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,720.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $944.56 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Janssen Pharmaceuticals, INC | $668.67 | 2021-2024 | Invega Sustenna, Xarelto |
| Otsuka America Pharmaceutical, INC. | $501.83 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $454.46 | 2021-2024 | Lybalvi |
| Teva Pharmaceuticals USA, INC. | $290.23 | 2024-2025 | Uzedy |
| Abbvie INC. | $242.98 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $195.80 | 2021 | |
| Neurocrine Biosciences, INC. | $125.80 | 2025 | |
| Vanda Pharmaceuticals INC. | $125.00 | 2024 | Fanapt |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $82.84 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $71.01 | 2023-2024 | Auvelity |
| Novo Nordisk INC | $54.23 | 2021-2023 | Ozempic, Rybelsus |
| Pfizer INC. | $47.39 | 2023 | |
| Phathom Pharmaceuticals, INC. | $33.64 | 2024 | Voquezna |
| Mylan Specialty L.P. | $32.36 | 2024 | Yupelri |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $22.70 | 2024 | Trintellix |
| Amgen INC. | $19.95 | 2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $17.30 | 2023 | Arexvy, Shingrix |
| Scilex Pharmaceuticals INC. | $15.38 | 2021 | |
| Lilly USA, LLC | $14.74 | 2023 | Mounjaro |
| Exact Sciences Corporation | $13.88 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Ilog listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.